Crohn's Disease Following Rituximab Treatment for Follicular Lymphoma in a Patient with Synchronous Gastric Signet Ring Cells Carcinoma: A Case Report and Literature Review

Cancer Res Treat. 2020 Oct;52(4):1291-1295. doi: 10.4143/crt.2020.406. Epub 2020 Jul 13.

Abstract

Recently, there have been a few reports of rituximab (RTX)-induced Crohn's disease, but there is no literature available on successful long-term treatment and the clinical outcome of this condition. We retrospectively analyzed the clinical data of a rare case of Crohn's disease induced by RTX administered as induction and prolonged maintenance therapy of a follicular lymphoma, diagnosed synchronously with a gastric signet ring cells carcinoma, treated at our hospital.

Keywords: Crohn’s disease; Gastric signet ring cells carcinoma; Lymphoma; Rituximab.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use*
  • Antineoplastic Agents, Immunological / adverse effects*
  • Budesonide / therapeutic use
  • Carcinoma, Signet Ring Cell / diagnosis
  • Carcinoma, Signet Ring Cell / drug therapy
  • Carcinoma, Signet Ring Cell / immunology
  • Crohn Disease / chemically induced
  • Crohn Disease / diagnosis
  • Crohn Disease / drug therapy
  • Crohn Disease / immunology*
  • Drug Therapy, Combination / methods
  • Humans
  • Induction Chemotherapy / adverse effects
  • Induction Chemotherapy / methods
  • Lymphoma, Follicular / diagnosis
  • Lymphoma, Follicular / drug therapy
  • Lymphoma, Follicular / immunology
  • Maintenance Chemotherapy / adverse effects
  • Maintenance Chemotherapy / methods
  • Male
  • Mesalamine / therapeutic use
  • Middle Aged
  • Neoplasms, Multiple Primary / diagnosis
  • Neoplasms, Multiple Primary / drug therapy
  • Neoplasms, Multiple Primary / immunology
  • Rituximab / adverse effects*
  • Stomach Neoplasms / drug therapy
  • Stomach Neoplasms / immunology
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Antineoplastic Agents, Immunological
  • Rituximab
  • Mesalamine
  • Budesonide